Eddingpharm in its US$140 million Series E financing led by OrbiMed and Sequoia.
DCP on its acquisition of a 9% stake in A-share listed Tonghua Dongbao Pharmaceutical Co., Ltd. from Dongbao Industrial Group Limited, for a consideration of approximately US$283 million.
MicroPort Cardiac Rhythm Management Limited in connection with its Series B financing with total investment proceeds of US$105 million from Hillhouse Capital and Yunfeng Capital.
MicroPort Medical Robot in connection with its financing with total investment proceeds of RMB 3 billion from Hillhouse Capital, CPE, etc.
Ant Group and other investors on its investment in Meixin Health, the leading innovative healthcare service group, with a total investment proceeds of RMB1 billion.
Anheart Therapeutics in connection with its Series A+, Series A-2, and Series B financing.
MitrAssist in connection with its restructuring, Series A and Series B financing.
Boyu Capital, 6 Dimensions Capital and other investors on their investment in Gloria Biotechnology, a wholly-owned subsidiary of Harbin Gloria Pharmaceuticals Co. (an A-share listed company), and on their acquisition of a 51% equity stake in Gloria Biotechnology.
PAG and CVC on their subscription of Series A preferred shares of Alphamab, a company dedicated to the development and commercialization of biopharmaceuticals for cancer treatment. PAG and CVC invested US$34 million and US$25 million, respectively.
Yunfeng Capital on its US$148 million equity investment in Livzon Biologics, a subsidiary controlled by Livzon Pharmaceutical Group Inc., an A-share listed company.
TPG Capital on its acquisition of a majority stake in OPC, a leading clinical trial group across Asia.